Search - tctmd.com

Displaying 121 - 140 of 1259

Sort: Relevancy | Date

News Conference News TCT 2016

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Yael L. Maxwell

November 02, 2016

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Andreas Baumbach

November 01, 2016

Presentation TCT 2016

Cerebral Embolic Protection I: The Sentinel Filter - Design Features and Updates from CLEAN-TAVI, SENTINEL RCT, and Others

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Axel Linke

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Ganesh Manoharan

November 01, 2016

Presentation TCT 2016

Transfemoral Large Hole Closure Devices: Manta, Inseal, and Others

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Alexandre Abizaid

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

New Valvuloplasty Devices III: Bard TRUE and TRUE-Flow Balloon Valvuloplasty - Technical Advantages and Clinical Applications

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Cheng-Han Chen

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

New Valvuloplasty Devices II: InterValve V8 Balloon Valvuloplasty - Technical Advantages and Clinical Applications

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Wesley R. Pedersen

November 01, 2016

Presentation TCT 2016

New Valvuloplasty Devices I: Pi-cardia Leaflex Aortic Valve Remodeling Therapy

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Michael Jonas

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: SENTINEL

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Alexandra J. Lansky

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Surveying the Global Landscape of TAVR Newcomers

Presenter: Ganesh Manoharan, Hendrik Treede, Martin B. Leon

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: ReACT

Presenter: Giulio Guagliumi, Ik-Kyung Jang, Niels R. Holm

November 01, 2016

Presentation TCT 2016

Xeltis: Design and Clinical Updates

Presenter: Ganesh Manoharan, Hendrik Treede, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Centera: Design and Clinical Updates

Presenter: Ganesh Manoharan, Hendrik Treede, Stephen G. Worthley

November 01, 2016

Presentation TCT 2016

Venus A Valve: Design and Clinical Updates

Presenter: Ganesh Manoharan, Hendrik Treede, Hasan Jilaihawi

November 01, 2016

Advertisement

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

Cerebral Embolic Protection I: The Sentinel Filter - Design Features and Updates from CLEAN-TAVI, SENTINEL RCT, and Others

Highlights (and my Interpretations) From: PARTNER I 5-YEAR Echo and PARTNER II Quality of Life

Transfemoral Large Hole Closure Devices: Manta, Inseal, and Others

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

New Valvuloplasty Devices III: Bard TRUE and TRUE-Flow Balloon Valvuloplasty - Technical Advantages and Clinical Applications

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

New Valvuloplasty Devices II: InterValve V8 Balloon Valvuloplasty - Technical Advantages and Clinical Applications

New Valvuloplasty Devices I: Pi-cardia Leaflex Aortic Valve Remodeling Therapy

Highlights (and my Interpretations) From: SENTINEL

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Surveying the Global Landscape of TAVR Newcomers

Highlights (and my Interpretations) From: ReACT

Xeltis: Design and Clinical Updates

Centera: Design and Clinical Updates

Venus A Valve: Design and Clinical Updates

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content